| Mrs Amy Reilly Trent, ANP | |
|
743 Spring St Ne, Gainesville, GA 30501-3715 | |
| (770) 219-9000 | |
| (770) 219-2625 |
| Full Name | Mrs Amy Reilly Trent |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 15 Years |
| Location | 743 Spring St Ne, Gainesville, Georgia |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1992028963 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 364SC0200X | Clinical Nurse Specialist - Critical Care Medicine | RN154502 (Georgia) | Secondary |
| 363LA2200X | Nurse Practitioner - Adult Health | RN154502 (Georgia) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Northeast Georgia Medical Center, Inc | Gainesville, GA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Georgia Heart Institute Llc | 4183848062 | 102 |
| Northeast Georgia Physicians Group Inc | 6901898386 | 646 |
News Archive
Medivir AB, the emerging research-based specialty pharmaceutical company focused on infectious diseases, today announces that the Company's commercialization partner, Meda AB, has launched Medivir's unique cold sore treatment Xerese in the United States.
Micell Technologies, Inc. today announced the release of preliminary data from the first-in-human clinical study of the MiStent Sirolimus Drug Eluting Coronary Stent System (MiStent DES), a thin-strut drug-eluting stent distinguished by a rapid-absorbing drug/polymer coating designed for controlled drug release.
We are pleased to announce that the Phase II clinical study of UF-021, product name Ocuseva, which we are developing as a therapeutic drug for retinitis pigmentosa, has been completed.
US researchers have identified a gene that appears to be responsible for the placebo effect.
› Verified 2 days ago
| Entity Name | Gwinnett Medical Group, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1780747469 PECOS PAC ID: 4284524166 Enrollment ID: O20040316000602 |
News Archive
Medivir AB, the emerging research-based specialty pharmaceutical company focused on infectious diseases, today announces that the Company's commercialization partner, Meda AB, has launched Medivir's unique cold sore treatment Xerese in the United States.
Micell Technologies, Inc. today announced the release of preliminary data from the first-in-human clinical study of the MiStent Sirolimus Drug Eluting Coronary Stent System (MiStent DES), a thin-strut drug-eluting stent distinguished by a rapid-absorbing drug/polymer coating designed for controlled drug release.
We are pleased to announce that the Phase II clinical study of UF-021, product name Ocuseva, which we are developing as a therapeutic drug for retinitis pigmentosa, has been completed.
US researchers have identified a gene that appears to be responsible for the placebo effect.
› Verified 2 days ago
| Entity Name | Northeast Georgia Physicians Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1891745212 PECOS PAC ID: 6901898386 Enrollment ID: O20040402001277 |
News Archive
Medivir AB, the emerging research-based specialty pharmaceutical company focused on infectious diseases, today announces that the Company's commercialization partner, Meda AB, has launched Medivir's unique cold sore treatment Xerese in the United States.
Micell Technologies, Inc. today announced the release of preliminary data from the first-in-human clinical study of the MiStent Sirolimus Drug Eluting Coronary Stent System (MiStent DES), a thin-strut drug-eluting stent distinguished by a rapid-absorbing drug/polymer coating designed for controlled drug release.
We are pleased to announce that the Phase II clinical study of UF-021, product name Ocuseva, which we are developing as a therapeutic drug for retinitis pigmentosa, has been completed.
US researchers have identified a gene that appears to be responsible for the placebo effect.
› Verified 2 days ago
| Entity Name | Gwinnett Physician Group, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1578574661 PECOS PAC ID: 9133211139 Enrollment ID: O20070822001035 |
News Archive
Medivir AB, the emerging research-based specialty pharmaceutical company focused on infectious diseases, today announces that the Company's commercialization partner, Meda AB, has launched Medivir's unique cold sore treatment Xerese in the United States.
Micell Technologies, Inc. today announced the release of preliminary data from the first-in-human clinical study of the MiStent Sirolimus Drug Eluting Coronary Stent System (MiStent DES), a thin-strut drug-eluting stent distinguished by a rapid-absorbing drug/polymer coating designed for controlled drug release.
We are pleased to announce that the Phase II clinical study of UF-021, product name Ocuseva, which we are developing as a therapeutic drug for retinitis pigmentosa, has been completed.
US researchers have identified a gene that appears to be responsible for the placebo effect.
› Verified 2 days ago
| Entity Name | Georgia Heart Institute Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1477976520 PECOS PAC ID: 4183848062 Enrollment ID: O20140616001425 |
News Archive
Medivir AB, the emerging research-based specialty pharmaceutical company focused on infectious diseases, today announces that the Company's commercialization partner, Meda AB, has launched Medivir's unique cold sore treatment Xerese in the United States.
Micell Technologies, Inc. today announced the release of preliminary data from the first-in-human clinical study of the MiStent Sirolimus Drug Eluting Coronary Stent System (MiStent DES), a thin-strut drug-eluting stent distinguished by a rapid-absorbing drug/polymer coating designed for controlled drug release.
We are pleased to announce that the Phase II clinical study of UF-021, product name Ocuseva, which we are developing as a therapeutic drug for retinitis pigmentosa, has been completed.
US researchers have identified a gene that appears to be responsible for the placebo effect.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mrs Amy Reilly Trent, ANP Po Box 742616, Atlanta, GA 30374-2616 Ph: (770) 219-8420 | Mrs Amy Reilly Trent, ANP 743 Spring St Ne, Gainesville, GA 30501-3715 Ph: (770) 219-9000 |
News Archive
Medivir AB, the emerging research-based specialty pharmaceutical company focused on infectious diseases, today announces that the Company's commercialization partner, Meda AB, has launched Medivir's unique cold sore treatment Xerese in the United States.
Micell Technologies, Inc. today announced the release of preliminary data from the first-in-human clinical study of the MiStent Sirolimus Drug Eluting Coronary Stent System (MiStent DES), a thin-strut drug-eluting stent distinguished by a rapid-absorbing drug/polymer coating designed for controlled drug release.
We are pleased to announce that the Phase II clinical study of UF-021, product name Ocuseva, which we are developing as a therapeutic drug for retinitis pigmentosa, has been completed.
US researchers have identified a gene that appears to be responsible for the placebo effect.
› Verified 2 days ago
Mrs. Nancy Fletcher Mccall, APRN-BC-CNSPMH Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 4375 Spainhill Road, Gainesville, GA 30504 Phone: 770-654-4599 | |
Shelley Charmaine Martin, CNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1240 Jesse Jewell Pkwy Se Ste 500, Gainesville, GA 30501 Phone: 770-536-9864 Fax: 770-297-5025 | |
Anela D Pearson, AGACNP-BC Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 743 Spring St Ne, Gainesville, GA 30501 Phone: 770-534-2020 Fax: 770-534-8025 | |
Terri Penna Kemmerer, CNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1240 Jesse Jewell Pkwy Se Ste 500, Gainesville, GA 30501 Phone: 770-536-9864 Fax: 770-297-5025 | |
Bryan Scott Engel, NP-C Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1250 Jesse Jewell Pkwy Se Ste 200, Gainesville, GA 30501 Phone: 770-297-7277 | |
Laura J Banner, NP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1315 Jesse Jewell Pkwy Ne Ste 300, Gainesville, GA 30501 Phone: 770-219-6520 | |
Molly Bruce, FNP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 1250 Jesse Jewell Pkwy Se Ste 200, Gainesville, GA 30501 Phone: 770-297-7277 |